Full Text View
Tabular View
Study Results
Related Studies
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
This study has been completed.
Study NCT00661544   Information provided by M.D. Anderson Cancer Center
First Received: April 15, 2008   Last Updated: May 21, 2009   History of Changes
Study Type: Interventional
Study Design: Open Label, Uncontrolled, Single Group Assignment
Conditions: Multiple Myeloma
Stem Cell Transplantation
Interventions: Drug: Arsenic Trioxide
Drug: Melphalan
Drug: Ascorbic Acid

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment Period: 03/31/2004 through 08/02/2005. All pariticipants recruited at U.T. M.D. Anderson Cancer Center.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Arsenic Trioxide + Vitamin C + Melphalan Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0)

Participant Flow:   Overall Study
  Arsenic Trioxide + Vitamin C + Melphalan
STARTED   48  
COMPLETED   48  
NOT COMPLETED   0  



  Baseline Characteristics
  Show Baseline Characteristics


  Outcome Measures

1.  Primary:   Response Rate   [ 3, 6 and 12 months ]


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Muzaffar H. Qazilbash, MD / Associate Professor
Organization: U.T. M.D. Anderson Cancer Center
phone: 713-745-3458


No publications provided


Responsible Party: U.T. M.D. Anderson Cancer Center ( Muzaffar H. Qazilbash, MD/Associate Professor )
Study ID Numbers: 2003-0603
Study First Received: April 15, 2008
Results First Received: March 13, 2009
Last Updated: May 21, 2009
ClinicalTrials.gov Identifier: NCT00661544     History of Changes
Health Authority: United States: Institutional Review Board